Stifel Financial’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Stifel Financial’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,335	Closed	-$311K	–	3460
2021 Q2	$311K	Buy	+8,335	New	+$255K	﹤0.01%	2880
2019 Q3	–	Sell	-12,814	Closed	-$202K	–	3016
2019 Q2	$202K	Sell	12,814 -1,195	-9%	-$16.3K	﹤0.01%	2713
2019 Q1	$201K	Buy	+14,009	New	+$161K	﹤0.01%	2594

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Stifel Financial's DRNA Position: Q3 2021 in Review

Stifel Financial sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 8,335 shares — an estimated $311K sold.

Stifel Financial first reported a position in DRNA in Q1 2019 and held it in 3 quarters. The position peaked at $311K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Stifel Financial reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Stifel Financial sold 8,335 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $311K.
Stifel Financial first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 3 quarters.
Stifel Financial's Dicerna Pharmaceuticals, Inc. position peaked at $311K in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Stifel Financial's 13F filing for Q3 2021, filed 15 Nov 2021.